FIELD: biotechnology.
SUBSTANCE: disclosed is a kit containing a bispecific antibody molecule and material required for genetic transduction of CD8+T-cells, wherein the bispecific antibody molecule comprises a CD8+T-cell-transducing antigen binding domain, and a tumour-specific antigen binding domain. Also disclosed is use of a pharmaceutical composition containing said bispecific antibody molecule, in combination with genetically transduced CD8+T-cells for treating oncological disease and methods of treating oncological disease.
EFFECT: present invention provides targeted mobilization of CD8+T-cells into a tumour using bispecific antibody molecules that can be used in adoptive therapy.
29 cl, 24 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED ANTIGEN-BINDING RECEPTORS | 2018 |
|
RU2825816C2 |
| COMBINATION CONTAINING MULTIFUNCTIONAL ANTIBODIES REDIRECTING T-CELLS AND CONTROL POINT MODULATORS, AND ITS APPLICATIONS | 2017 |
|
RU2773655C2 |
| MULTI-SPECIFIC ANTIBODIES INTENDED FOR USE IN TREATMENT OF URINARY TRACT NEOPLASM | 2017 |
|
RU2766358C2 |
| BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY | 2005 |
|
RU2433831C2 |
| USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, IN COMBINATION WITH COSTIMULATION 4-1BB | 2020 |
|
RU2822092C2 |
| METHOD FOR PRODUCING HUMAN T-CELL RECEPTOR SPECIFIC TO EPITOPE 112-120 (KVAELVHFL) OF MAGE-A3 RECEPTOR | 2024 |
|
RU2840503C1 |
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| METHOD AND COMPOSITIONS FOR CELL IMMUNOTHERAPY | 2013 |
|
RU2700765C2 |
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
| PHARMACEUTICAL COMPOSITION POSSESSING ANTITUMOUR EFFECT, AND METHOD FOR REDUCING PD-L1 INHIBITING EFFECT ON HUMAN T-CELLS | 2016 |
|
RU2688692C2 |
